News and Announcements
Immuron Clarifies Terms of Debenture with Paladin Labs.
- Published February 09, 2012 2:43PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The Company has become aware of some misinformation regarding the terms of the Convertible Debenture (Agreement) entered into with Paladin Labs Inc. (Paladin), which was announced to the ASX on 16th January 2012. Specifically, the misinformation relates to the assets of the company that are encumbered under the debenture and could have been interpreted to, erroneously, include Immuron’s intellectual property.
Immuron’s Intellectual Property is not encumbered under the Debenture in any way. In view of Immuron’s stated principal focus to commercialize all of its products and intellectual property remains absolutely unfettered. This principle was vital in Immuron’s board unanimously approving the Paladin transaction on 28 November 2011.
—–
To view the full article, please click the link below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
